VivoSeq
Other

ART

0

Pipeline Programs↗

112

Active Trials↗

135

Companies Involved↗

ART is an early-stage landscape with 0 programs across 135 companies. The most active players are Eli Lilly, Johnson & Johnson, Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

72/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

1,048

clinical trials

Completed793 · 76%
Terminated72 · 7%
Recruiting58 · 6%
Unknown status43 · 4%
Not yet recruiting27 · 3%
Withdrawn24 · 2%
Other31 · 3%

Clinical Trials

Trial Activity

1048 trials

Losartan and Emotional Learning
Recruiting·UUniversity of Oxford·Phase 1·NCT06628154·60 enrolled
A Study of AMDX-2011P in Participants With CAA
Recruiting·AAmydis Inc.·Phase 2·NCT05709314·25 enrolled
Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
Recruiting·WWright State University·Phase 1·NCT04520217·40 enrolled
The Effect of Losartan on Cephalexin
Recruiting·—·Phase 1·NCT07300670·12 enrolled
Dose-Escalation Study of Artesunate Patients With IPF
Recruiting·—·Phase 1·NCT05988463·15 enrolled
Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants
Recruiting·SShenzhen Salubris Pharmaceuticals Co., Ltd.·Phase 4·NCT07174830·54 enrolled
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Recruiting·CCorvus Pharmaceuticals, Inc.·Phase 2·NCT07441395·200 enrolled
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Recruiting·KKura Oncology, Inc.·Phase 1·NCT05735184·420 enrolled
Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients
Recruiting·TTRB Chemedica·Phase 3·NCT04318041·128 enrolled
Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants
Recruiting·SShanghai JMT-Bio Inc.·Phase 1·NCT07419698·44 enrolled
A Multiple Ascending Dose Study Evaluating the Safety and Tolerability of a Novel Formulation of QRL-101 in Healthy Participants
Recruiting·QQurAlis Corporation·Phase 1·NCT07421778·48 enrolled
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
Recruiting·AstraZeneca logoAstraZeneca·Phase 4·NCT07308574·20 enrolled
Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis
Recruiting·FFirst Affiliated Hospital of Wannan Medical College·Phase 3·NCT06225752·5,452 enrolled
Chitosan Phonophresis on Cervical IN Smartphone Addicted Users
Recruiting·OOctober 6 University·N/A·NCT06491992·30 enrolled
A Study of Single and Multiple Ascending Doses of H021 in Healthy Participants
Recruiting·JJiangsu Carephar Pharmaceutical Co., Ltd.·Phase 1·NCT06627556·64 enrolled
Page 1 of 70

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)